Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients

Journal of Neural Transmission

Volumn 121, Issue 6, 2014, Pages 643-648

  Müller, Thomas ^a,b   Muhlack, Siegfried ^b  

^a St Joseph Hospital   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Cysteine; Cysteinyl glycine; Oxidative stress; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CYSTEINE; CYSTEINYLGLYCINE; ENTACAPONE; FREE RADICAL; GLUTATHIONE; LEVODOPA; ANTIPARKINSON AGENT; CATECHOL DERIVATIVE; CATECHOL METHYLTRANSFERASE; DIPEPTIDE; METHYLDOPA; NITRILE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG TRANSFORMATION; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; AGED; ANALYSIS OF VARIANCE; BLOOD; DRUG DELIVERY SYSTEM; METABOLISM; MIDDLE AGED; REVERSED PHASE LIQUID CHROMATOGRAPHY; TIME;

AGED; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; CARBIDOPA; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CHROMATOGRAPHY, REVERSE-PHASE; CYSTEINE; DIPEPTIDES; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LEVODOPA; MALE; METHYLDOPA; MIDDLE AGED; NITRILES; PARKINSON DISEASE; TIME FACTORS;

EID: 84901852639     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1155-1     Document Type: Article

References (26)

1. Allen GF, Ullah Y, Hargreaves IP, Land JM, Heales SJ (2013) Dopamine but not l-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson's and other dopamine deficiency states. Neurochem Int 62:684-694
2. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K (2004) Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508
3. Fujita Y, Izawa Y, Ali N, Kanematsu Y, Tsuchiya K, Hamano S, Tamaki T, Yoshizumi M (2006) Pramipexole protects against H2O2-induced PC12 cell death. Naunyn Schmiedebergs Arch Pharmacol 372:257-266
4. Inden M, Kitamura Y, Tamaki A, Yanagida T, Shibaike T, Yamamoto A, Takata K, Yasui H, Taira T, Ariga H, Taniguchi T (2009) Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochem Int 55:760-767
5. Jugel C, Ehlen F, Taskin B, Marzinzik F, Müller T, Klostermann F (2013) Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs. PLoS ONE 8:e66639
6. Miklya I, Knoll B, Knoll J (2003) A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. Life Sci 72:2641-2648
7. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA (1997) Effect of l-dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20:55-66
8. Müller T (2011) Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert Opin Drug Metab Toxicol 7:847-855
9. Müller T (2013) Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease. Expert Rev Neurother 13:707-718
10. Müller T, Kuhn W (2009) Cysteine elevation in levodopa-treated patients with Parkinson's disease. Mov Disord 24:929-932
11. Müller T, Muhlack S (2011) Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients. Mov Disord 26:543-546
12. Müller T, Muhlack S (2012) Cysteine decrease following acute Levodopa intake in patients with Parkinson's disease. Neurosci Lett 521(1):37-39
13. Müller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, Goetze O (2006) Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol 29:61-67
14. Müller T, Ander L, Kolf K, Woitalla D, Muhlack S (2007) Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/ entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease. J Neural Transm 114:1457-1462
15. Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A (2013) Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 19:501-507
16. NINDS NET-PD Investigators (2007) A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68:20-28
17. Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287:1653-1661
18. Przuntek H, Conrad B, Dichgans J, Kraus PH, Krauseneck P, Pergande G, Rinne U, Schimrigk K, Schnitker J, Vogel HP (1999) SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 6:141-150
19. Riederer P, Lachenmayer L, Laux G (2004) Clinical applications of MAO-inhibitors. Curr Med Chem 11:2033-2043
20. Riederer P, Gerlach M, Müller T, Reichmann H (2007) Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease. Parkinsonism Relat Disord 13:466-479
21. Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K (2013) Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12:747-755
22. Shults CW (2005) Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacol Ther 107:120-130
23. Smeyne M, Smeyne RJ (2013) Glutathione metabolism and Parkinson's disease. Free Radic Biol Med 62:13-25
24. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25:2649-2653
25. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54:93-101
26. Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62:236-249